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Summary 
A new series of water-soluble (R-benzoyloxy) methyl esters of aspirin bearing at the benzoyl ring 
both alkyl chains containing nitric oxide (NO)-releasing nitrooxy groups and solubilizing moieties, 
was synthesized, and the products evaluated as true aspirin pro-drugs. Most products are solid 
substances and all posses good water solubility. They are quite stable in acid solutions (pH=1) and 
less stable at physiological pH. In human serum they are immediately metabolized by esterases, 
producing a mixture of aspirin (ASA), salicylic acid (SA), and of the related NO-donor benzoic 
acids, with other minor products. Due to aspirin release, the pro-drugs are capable of inhibiting 
collagen-induced platelet aggregation of human platelet-rich plasma. The simple NO-donor benzoic 
acids 28 and 48, studied as representative models of the whole class of benzoic acids formed 
following metabolism of the prodrugs in serum, did not trigger antiaggregatory activity when tested 
at 300 µM concentration. Only 28 displays quite potent NO-dependent vasodilatatory action. For 
two selected pro-drugs, 38 and 49, in vivo gastrotoxicity and anti-inflammatory properties are also 
reported: their anti-inflammatory activities are similar to that of aspirin when tested in the 
carrageenan-induced paw edema assay in rats. The gastrotoxicity the two pro-drugs was lower than 
that of aspirin in a lesion model in rats. 
Introduction 
Nitric oxide (NO)-donor aspirins (NO-ASA) are a class of products that has received particular 
attention in recent years.1,2 The pharmacological rationale for developing them was that NO 
displays gastrosparing properties and consequently could be expected to reduce the well-known 
gastrotoxicity of ASA, without reducing its antithrombotic and anti-inflammatory properties.3-5 NO-
ASAs have the general structure 1 (Chart 1) in which the carboxylic group of acetylsalicylic acid 
(ASA) is linked through an enzymatically-labile ester bridge to a substructure containing a NO-
donor moiety, belonging to the nitrate, furoxan, NONOate class. Examples of such hybrids are 
reported in the literature.6-8 The action of these substances is complex, and there is no clear 
evidence to date that they are true pro-drugs of ASA, namely that they are capable of releasing ASA 
in the plasma or other tissues. The absence of a negative charge, which conversely is present on 
ASA at physiological pH (ASA, pKa=3.5), renders their acetyloxy group highly susceptible to 
enzymatic cleavage.9 These products should thus be considered pro-drugs of salicylic acid (SA) 
rather than of ASA. We recentl showed that (nitrooxyacyloxy)methyl esters of ASA and related 
carbonates are true ASA pro-drugs (2, 3 Chart 1).10,11 In these structures the deacetylation rate 
constant is lower than the hydrolytic rate constant of the carbonyloxymethyloxycarbonyl moiety, 
and consequently the products are able to release ASA in amounts that depend on the structure of 
the NO donor acyl moiety. One problem with these double esters is their poor water solubility; 
many are oily in nature. This study describes a new series of (nitrooxyacyloxy)methyl esters of 
ASA, which are true ASA pro-drugs and that posses good water solubility and a solid physical 
state. In these products, the NO-donor nitrooxyacyloxy moiety comprises the benzoyloxy scaffold, 
bearing a nitrooxyalkyloxy chain at the para position, and a solubilizing substructure at the meta 
position (Chart 2). In most of the derivatives (38-44) the solubilizing substructure is a 
metabolically-labile aminoacyloxy group (I, Chart 2); in the case of compound 49 (Chart 2), the 
morpholinomethyl solubilizing substructure is directly jointed to the aromatic ring. The synthesis, 
solubility, stability in different media, release of ASA, together with in vitro platelet 
antiaggregatory profile of all these new pro-drugs are discussed. The in vivo gastrotoxicity and anti-
inflammatory properties are also reported for two selected compounds, 38 and 49. 
Chemicals. The products bearing aminoacyloxy groups were obtained as reported in Schemes 1 - 3. 
The commercially-available 3,4-dihydroxybenzaldehyde (4) was bromoalkylated with 1,3-
dibromopropane in acetonitrile solution to give 5 that, in turn, was transformed by action of AgNO3 
into the related nitrooxy analogue 7. This intermediate was reacted under inert atmosphere with the 
appropriate tert-butoxycarbonyl (BOC) protected amino acid in CH2Cl2 solution, in the presence of 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC·HCl) and 4-
(dimethylamino)pyridine (DMAP), to afford the related aminoacyloxy substituted aldehydes 9, 11-
14. The corresponding acids 15, 17-20 were obtained by oxidation with KMnO4 in acetone solution. 
The acid 16 and its intermediates 10, 8 were obtained in the same manner as its inferior homologue 
15, the only difference being that the starting material was the chloro substituted compound 6. 
Coupling of these acid derivatives 15-20 with ASA chloromethyl ester 29, in the presence of 
Cs2CO3, gave the oxymethyloxy esters 30-35, and subsequent removal of BOC-protection in 
dioxane containing HCl yielded the desired compounds 38-43. The final para-nitroxybutyloxy 
product 39 and the its intermediates 16, 10, 8, were obtained in the same manner as its inferior 
homologue 38 and related intermediates. For the preparation of the dinitrooxy substituted pro-drug 
44 3,4-dihydroxybenzaldehyde (4) was alkylated with allylbromide to give the unsaturated aldehyde 
21. This latter was treated with (BOC)-protected β-alanine to give 22, following the general 
conditions described above for the preparation of the (BOC)-protected aminoacyloxy substituted 
aldehydes. This intermediate was transformed by action of iodine and AgNO3 into the 
dinitrooxyester 23, which, in turn was oxidized with KMnO4 to the corresponding acid 24. The final 
compound 44 was obtained from 24 through the intermediate 36, using the procedures described 
above to prepare the aminoacyloxy substituted pro-drugs from the related acids. 
Scheme 2 reports the synthesis of the simple NO-donor benzoic acids 28. In particular, the ester 
derivative 27 was obtained starting from the methyl ester of 3,4-dihydroxybenzoic acid 25, in the 
same manner as its aldehyde analogue 7. 27 was then hydrolyzed to the corresponding carboxylic 
acid 28 with NaOH in a THF/H2O mixture heated to 40 °C. 
Scheme 4 reports the synthetic pathway followed to obtain the target product 49 containing the 
morpholino moiety as solubilizing group. The ester 45 treated with 1,3-dibromopropane in 
acetonitrile solution gave rise to the bromocompound 46. This product, by action of AgNO3 in 
acetonitrile solution, was transformed into the nitrooxy analogue 47, in turn hydrolyzed to the 
related acid 48, which was coupled with 29 to give the desired final structure. 
All the basic products were successfully transformed into the related hydrochlorides, with the sole 
exception of the morpholino derivative 49, which was characterized as an oxalate. Most of these 
salts are solid compounds having well-defined melting points (Table 1). Products 39 and 41, which 
are both superior homologues of 38, the former at the aminoacyloxy chain, the latter at the 
nitrooxyalkyloxy moiety, are oily. Compound 44, formally derived from 38 by introducing a second 
nitrooxy group α-positioned to the first, is a foam. 
Water solubility. The water solubility values of all compounds described here are given in Table 1. 
All products display good water solubility, in most cases higher than that of ASA (3 g/l, The Merck 
Index Fourteenth Edition). For the solid hydrochlorides, the higher the solubility, the lower the 
melting point.  
Hydrolysis studies. Most of the pro-drugs described here (compounds 38-44) contain three 
substructures susceptible to hydrolysis: the acetyloxy group, the aminoacyloxy group, and the 
carbonyloxymethyloxycarbonyl moiety. The possible routes whereby these products can hydrolyze 
are reported in Scheme 5. Hydrolysis was assessed by high performance liquid chromatography 
(HPLC) in pH 1 and pH 7.4 buffered solutions, as well as in human serum. In human serum, 
hydrolysis is catalyzed by carboxylesterases, ubiquitous enzymes that display broad substrate 
specificity: the same ester can often be hydrolyzed by more than one enzyme.12 In human serum, 
the fate of all compounds was very similar: the observed half-lives were < 1 min (see Table 1). The 
metabolites were monitored for 6 h. After 10 minutes, only ASA, SA, IV, and traces of II and III 
were present: this means that the aminoacyloxy and the carbonyloxymethyloxycarbonyl moieties 
hydrolyze simultaneously, and much more faster than the related acetyloxy functions. After 6 h, 
only SA and IV, accompanied by traces of ASA, were present. Figure 1 shows the concentration 
over time of the metabolites of compound 38, as an example of the performance of the class as a 
whole. This is an interesting result, and shows that these products are true ASA pro-drugs. Maximal 
ASA production is reached for all compounds after 2-5 min. These values, expressed as % of the 
initial concentration of the compounds, are reported in Table 1. They are similar for all products, 
and fall in the range 50-57%. Table 1 also gives the areas under the ASA release curves, measured 
after ten minutes’ incubation (AUC0-10min). They do not entirely parallel the corresponding max 
ASA % values, which suggests that the substitution pattern at the benzoyl ring exerts some 
influence on the hydrolysis of the carbonyloxymethyloxycarbonyl moieties. 
The products are more stable in physiological solution (pH=7.4 phosphate buffer) than in serum: 
after 3 hours’ incubation, the sole metabolite formed was III. The hydrolysis strictly followed first-
order kinetic, and the observed pseudo-first-order constants (kobs) were calculated from the slopes of 
linear plots of the logarithm of the remaining ester against time: the corresponding half-lives 
(Table) were obtained from the eq 1. 
t1/2 = 0.693/kobs (1) 
The most stable pro-drugs are compounds 39 (86 min), 38 (57 min), and 44 (20 min), bearing the β-
aminopropionyloxy chain at the 3-position of the benzoyl ring. The other compounds show t1/2 
values in the range 10-15 min. 
In pH=1 buffered solution, all products remained 70-90% unchanged after 3h (Table 1); during this 
time, only III had formed. 
Unlike the products discussed above, the pro-drug 49 bears the water-solubilizing 
morpholinomethyl group directly linked to the benzoyl scaffold, rather than through a vulnerable 
ester bridge. Consequently, only the acetyloxy and the carbonyloxymethyloxycarbonyl moieties 
undergo hydrolysis, with a consequent decrease in the number of possible metabolites (see Scheme 
5). This product is more stable in serum than the pro-drugs discussed previously , due to the lack of 
the very vulnerable aminoacyloxy function. Like the other pro-drugs, its deacetylation rate constant 
is lower than the hydrolytic rate constant of the carbonyloxymethyloxycarbonyl moiety, which 
enables ASA to be present among the metabolites. The hydrolysis strictly follows a first order 
kinetics. Its half-life, calculated from the observed pseudo-first-order rate constant, is 2.2 min. 
Figure 2 shows the concentrations of the metabolites over time for this product . The maximum 
concentration of aspirin is reached after 6 min, and the amount of aspirin released (% max and AUC 
values) is lower than the values measured for all other pro-drugs (see Table 1). After 6 h, only 48, 
SA, and traces of ASA were present. The compound is very stable, not only in pH=1 buffered 
solution, but also at physiological pH. 
Pharmacological studies. 
Platelet Antiaggregatory Activity. Antiaggregatory activity of the new NO-aspirins was assessed 
through collagen-induced platelet aggregation of human platelet rich plasma (PRP), taking ASA as 
reference standard. The inhibitory effect of a compound was tested by adding it to PRP 10 min 
before addition of the stimulus. All products displayed a concentration-dependent inhibitory effect. 
Their antiaggregatory potencies, expressed as IC50, are in Table 1. As previously mentioned, 
compounds IV and 48 are the metabolites formed rapidly from the pro-drugs under study, under the 
action of serum esterases. The antiaggregatory action of 28 and 48, chosen as prototypes of these 
acid metabolites, was likewise evaluated. No antiaggregatory activity was observed when the 
products were tested at 300 µM concentration, meaning that NO does not play a significant role in 
the antiaggregatory effect of these pro-drugs, and that this activity is largely due to their capacity to 
produce ASA. The relationship between AUC0-10min and IC50 values for the entire series of pro-
drugs studied is depicted in Figure 3. 
Vasodilator activity. All the pro-drugs can be expected to display vasodilator properties in vivo, due 
to the rapid formation of the relative NO-donor benzoic acid metabolites (IV and 48) under the 
action of plasma esterases. The vasodilator activity of two selected acids, 28 and 48, chosen as 
prototypes of these metabolites, was evaluated on endothelium-denuded rat-aorta strips, 
precontracted with phenylephrine. The first compound (28), which contains the meta-
hydroxybenzoic acid moiety that is common to all the aminoacyloxy-substituted pro-drugs, was 
found to relax the contracted tissue in a concentration-dependent manner. Its potency, expressed as 
EC50, is in Table 1. When the experiments were repeated in the presence of 1 µ ODQ (1H-
[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one), a known inhibitor of soluble guanylate cyclase (sGC), 
the potency decreased (Table 1), in keeping with NO-induced activation of sGC being the 
mechanism underlying the vasodilator effect. Conversely, the second compound (48) was inactive 
as a vasodilator, after testing it at up to 100 µM concentration. This product contains the same para-
nitrooxy alkyl chain as 28, but the water solubilizing group is covalently attached to the benzoic 
acid scaffold. The lipophilic-hydrofilic balance of the two products differs (28, logD
7.4 = -0.80; 48, 
logD7.4 = -1.30) as do their steric and electronic properties. The former at physiological pH exists 
principally as an anionic species (anion form >99%; pKa COOH = 4.41) while the latter exists as a 
mixture of anion and zwitterion species (anion form = 54%, zwitterion form = 46%; pKa COOH = 
3.90, pKa MORPHOLINE = 7.33). These diverse physico-chemical profiles should give the two products 
different capacities both to reach and to interact with the target enzyme involved in NO production, 
thus affording different vasodilator behaviour. This does not rule out that 48 could release NO in a 
more complex biological environment: experiments incubating this compound in liver homogenate 
pointed to a time-dependent production of nitrite and nitrate (NOx), the oxidised metabolites of NO 
derived from biotransformation of organic nitrates (data not shown). 
Anti-inflammatory activity. The two NO-donor ASA pro-drugs, 38 and 49, and ASA itself, as 
reference drug, were tested for their anti-inflammatory activity by the carrageenan-induced paw 
edema test in conscious rats (six per group). The intraplantar injection of carrageenan produced an 
immediate increase in the paw volume, the inflammatory response peaking 4-5 h hours after 
carrageenan injection. The intragastric administration of 120 mg/kg ASA, just prior to carrageenan 
injection, led to a significant reduction in edema (57.4 ± 6.8 %, P < 0.01 versus vehicle-treated 
controls) assessed 3 h after ASA administration. Both pro-drugs, 38 and 49, administered at doses 
equimolar to 120 mgkg-1 ASA, caused a significant reduction in paw edema (54.9 ± 6.6 % and 51.5 
± 4.3 % respectively, P > 0.01 versus vehicle-treated controls). The degree of reduction achieved 
following the administration of the two pro-drugs was comparable to that caused by ASA (Figure 
4A). 
Acute Gastric Mucosal Damage. The two NO-donor ASA pro-drugs, 38 and 49, and ASA itself, as 
reference drug, were administered intragastrically to conscious rats (six per group) and after 3 h the 
lesion index of each rat stomach was assessed. ASA, at a dose of 120 mg/kg, resulted in the 
development of macroscopically-detectable lesions located in the gastric mucosa, and characterized 
by necrosis and hemorrhage, the lesion index being 55.3 ± 10.4. In contrast, neither pro-drug, in a 
dose equimolar to 120 mgkg-1 ASA, exerted macroscopically-detectable damaging effects on the 
gastric mucosa (Figure 4B). 
 
Conclusions 
We have developed a new class of (benzoyloxy)methyl esters of ASA, bearing, at the benzoyl ring, 
both alkyl chains containing NO-releasing nitrooxy groups and aminoacyloxy solubilizing moieties. 
The products were characterized as salts, and most of them are solid compounds with well-defined 
melting points. The entire class display good water solubility and acid stability. The products are 
rapidly metabolized in physiological conditions. In human serum, under the action of esterases, the 
aminoacyloxy and the carbonyloxymethyloxycarbonyl moieties simultaneously hydrolyze, much 
more rapidly than do the related acetyloxy functions. The resulting mixture of metabolites includes 
significant amounts of ASA, and consequently these compounds may be considered true NO-donor 
ASA-prodrugs. All the products display good antiaggregatory properties as tested on collagen-
induced platelet aggregation of human platelet-rich plasma; this activity is roughly related to the 
amount of ASA released in the first ten minutes’ incubation. The benzoic acid derivative 28, 
containing the meta-hydroxybenzoic acid moiety and studied as prototype of the acid metabolites 
deriving from the aminoacyloxy substituted pro-drugs, is endowed with NO-dependent vasodilator 
activity, unlike 48, in which the solubilizing group remains covalently attached to the benzoic acid 
scaffold. The related pro-drugs 38, 49 display in vivo anti-inflammatory properties and reduced 
gastrotoxicity as tested on rats.  
As a whole, based on their pharmacological and physico-chemical profiles, the pro-drugs described 
here represent an improved class of NO-donor ASA pro-drugs in comparison to the related less 






1H and 13C NMR spectra were recorded on a Bruker Avance 300 at 300 and at 75 MHz, 
respectively, using SiMe4 as internal standard. The following abbreviations are used to indicate 
peak multiplicity: s=singlet, d=doublet, t=triplet, m=multiplet, br s=broad signal. Low resolution 
mass spectra were recorded with a Finnigan-Mat TSQ-700. Melting points were determined with a 
capillary apparatus (Buchi 540). Flash column chromatography was performed on silica gel (Merck 
Kieselgel 60, 230-400 mesh ASTM); PE stands for 40-60 petroleum ether. The progress of the 
reactions was monitored by thin layer chromatography (TLC) on 5 cm × 20 cm plates, with layer 
thickness 0.25 mm. Anhydrous sodium sulfate was used as the drying agent for the organic phases. 
Organic solvents were removed under vacuum at 30 °C. Elemental analyses (C, H, N) were 
performed by REDOX (Monza), and the results are within 0.4% of the theoretical values. 
Compounds 2913, 4514 were synthesized as indicated in the literature. 
4-(3-Bromopropoxy)-3-hydroxybenzaldehyde (5) 
A solution of 4 (5.00 g, 36.22 mmol), 1,3-dibromopropane (7.35 mL, 72.44 mmol) and KHCO3 
(4.35 g, 43.46 mmol) in CH3CN (100 mL) was refluxed for 4 hours. The mixture was then poured 
into H2O (50 mL) and extracted with EtOAc (50 mL); the organic layer was washed twice with a 
saturated solution of NaHCO3 (50 mL) and extracted twice with 2N NaOH (50 mL). The last 
acqueous layers were acidified with 6M HCl and then extracted with EtOAc (3 × 50 mL). The 
combined organic layers were dried with MgSO4, filtered, and concentrated under reduced pressure 
to give the title compound as a pale yellow semisolid; yield: 47 %. 1H-NMR (CDCl3)  2.43 (qi, 
2H, -OCH2CH2-), 3.60 (t, 2H, -CH2Br), 4.32 (t, 2H, -OCH2-), 5.88 (s, 1H, OH), 7.01 (d, 1H, C6H3), 
7.42 (m, 1H, C6H3), 7.44-7.46 (m, 1H, C6H3), 9.85 (s, 1H, -CHO). 
13C-NMR (CDCl3)  29.3, 31.8, 
66.9, 111.2, 114.4, 124.6, 130.8, 146.2, 150.9, 191.1. MS (CI) m/z 259/261 (M+1)+. 
4-(4-Chlorobutoxy)-3-hydroxybenzaldehyde (6) 
A solution of 4 (1.00 g, 7.24 mmol), 1-bromo-4-chlorobutane (2.50 mL, 21.7 mmol) and KHCO3 
(870 mg, 8.69 mmol) in CH3CN (20 mL) was refluxed for 14 hours. The mixture was then poured 
into H2O (30 mL) and extracted with EtOAc (30 mL); the organic layer was washed twice with a 
saturated solution of NaHCO3 (30 mL) and extracted with 2N NaOH (3 × 30 mL). The last 
acqueous layers were acidified with 6M HCl and then extracted with EtOAc (3 × 30 mL). The 
combined organic layers were dried with MgSO4, filtered, and concentrated under reduced pressure 
to give the title compound as a white solid; yield: 60 %. m.p. 58-59 °C (PE/Toluene 1/1 v/v). 1H-
NMR (CDCl3)  1.95-2.12 (m, 4H, -OCH2CH2-), 3.65 (t, 2H, -CH2Cl), 4.20 (t, 2H, -OCH2CH2-), 
5.93 (s, 1H, OH), 6.97 (d, 1H, C6H3), 7.41-7.46 (m, 2H, C6H3), 9.84 (s, 1H, -CHO). 
13C-NMR 
(CDCl3)  26.9, 29.6, 45.0, 68.9, 111.4, 114.8, 125.0, 131.2, 146.7, 151.6, 191.6. MS (CI) m/z 
229/231 (M+1)+. 
4-(Allyloxy)-3-hydroxybenzaldehyde (21) 
A solution of 4 (2.00 g, 14.48 mmol), allyl bromide (1.20 mL, 14.48 mmol) and KHCO3 (1.74 g, 
17.37 mmol) in CH3CN (20 mL) was refluxed for 4 hours. The mixture was then poured into H2O 
(50 mL) and extracted with EtOAc (50 mL); the organic layer was washed twice with a saturated 
solution of NaHCO3 (50 mL) and extracted twice with 2N NaOH (50 mL). The last acqueous layers 
were acidified with 6M HCl and then extracted with EtOAc (3 × 50 mL). The combined organic 
layers were dried with MgSO4, filtered, and concentrated under reduced pressure to give the title 
compound as a pale yellow semisolid; yield: 40 %. m.p. 57-60 °C (iPr2O). 
1H-NMR (CDCl3)  4.69 
(d, 2H, -OCH2-), 5.34-5.46 (m, AMX-like system, 2H, -CH=CH2), 5.99-6.13 (m, AMX-like system, 
2H, -CH=CH2 + -OH), 6.96 (d, 2H, C6H3), 7.38-7.46 (m, 2H, C6H3), 9.83 (s, 1H, -CHO). 
13C-NMR 
(CDCl3)  69.9, 111.5, 114.4, 119.2, 124.4, 130.6, 131.8, 146.3, 150.9, 191.2. MS (CI) m/z 179 
(M+1)+. 
Methyl 4-(3-bromopropoxy)-3-hydroxybenzoate (31) 
A solution of methyl 3,4-dihydroxybenzoate (2.10 g, 12.5 mmol), 1,3-dibromopropane (3.80 mL, 
37.5 mmol) and KHCO3 (1.50 g, 14.53 mmol) in CH3CN (20 mL) was refluxed for 5 hours. The 
mixture was then poured into H2O (50 mL) and extracted twice with EtOAc (30 mL); the combined 
organic layers were washed with brine (10 mL), dried with MgSO4, filtered, and concentrated under 
reduced pressure. The crude product was purified by flash chromatography (PE/EtOAc 9/1 v/v to 
PE/EtOAc 7/3 v/v) to give the title compound as a white solid; yield: 25 %. m.p. 106.5-107.5 °C 
(iPr2O). 
1H-NMR (CDCl3)  2.39 (qi, 2H, -OCH2CH2-), 3.58 (t, 2H, -CH2Br), 3.88 (s, 3H, -OCH3), 
4.26 (t, 2H, -OCH2CH2-), 5.75 (sbr, 1H, OH), 6.90 (d, 1H, C6H3), 7.57-7.61 (m, 2H, C6H3). 
13C-
NMR (CDCl3)  29.4, 31.8, 50.0, 66.7, 110.8, 115.9, 122.8, 132.1, 145.3, 149.4, 166.8. MS (CI) m/z 
289/291 (M+1)+. 
Methyl 4-(3-bromopropoxy)-3-(morpholin-4-ylmethyl)benzoate (46) 
To a solution of 27 (2.00 g, 7.90 mmol) in CH3CN (12 mL) K2CO3 (1.66 g, 12.0 mmol) and 1,3-
dibromopropane (3.96 mL, 39.0 mmol) were added and the mixture was heated under reflux for 6 h. 
The cooled reaction mixture was then poured into H2O (50 mL) and extracted with EtOAc (3 x 50 
mL) The combined organic layers were washed with H2O (25 mL), brine (25 mL), dried with 
MgSO4, filtered, and concentrated under reduced pressure. The crude product was purified by flash 
chromatography (PE/EtOAc 60/40 v/v) to give the title compound (1.12 g) as a colourless oil; yield: 
38%. 1H-NMR (CDCl3) d 2.36 (qi, 2H, -OCH2CH2-), 2.48 (t, 4H, -CH2NCH2-), 3.53 (s, 
2H, -ArCH2-N), 3.64-3.73 (m, 6H, -CH2OCH2-, -CH2Br), 3.89 (s, 3H, -OCH3), 4.19 (t, 2H, -OCH2), 
6.90 (d, 1H, C6H3), 7.94 (d, 1H, C6H3), 8.01 (s, 1H, Arom). 
13C-NMR (CDCl3) d 29.8, 32.2, 51.9, 
53.7, 56.7, 65.5, 67.0, 110.8, 122.4, 126.1, 130.6, 132.3, 160.6, 166.9. 
General procedure for the preparation of nitrooxy derivatives (7, 8, 47) 
A solution of the appropriate bromo/chloro derivative (1.93 mmol) and AgNO3 (0.82 g, 4.82 mmol) 
in CH3CN (15 mL) was stirred at 70 °C for 14h. Brine was then added to precipitate the excess of 
AgNO3, the mixture was filtered through Celite® and concentrated under reduced pressure. The 
residue was treated with EtOAc (50 mL) and H2O (50 mL). After separation, the aqueous layer was 
extracted twice with EtOAc (10 mL). The combined organic layers were dried with MgSO4, 
filtered, and concentrated under reduced pressure. The crude product thus obtained was purified, if 
necessary, by flash chromatography. Chromatographic eluents and yields of the products were as 
follows. 
3-(4-Formyl-2-hydroxyphenoxy)propyl nitrate (7) 
The crude product was used without any purification as a yellow oil; yield 89 %. 1H-NMR (CDCl3) 
 2.33 (qi, 2H, -OCH2CH2-), 4.27 (t, 2H, -OCH2CH2-), 4.67 (t, 2H, -CH2ONO2), 5.76 (sbr, 1H, -
OH), 6.97 (d, 1H, C6H3), 7.42 (m, 1H, C6H3), 7.44-7.47 (m, 1H, C6H3), 9.85 (s, 1H, -CHO). 
13C-
NMR (CDCl3)  26.9, 65.3, 69.6, 111.1, 114.7, 124.4, 131.1, 146.1, 150.5, 190.8. MS (CI) m/z 242 
(M+1)+. 
4-(4-Formyl-2-hydroxyphenoxy)butyl nitrate (8) 
The crude product was used without any purification as yellow solid; yield 63 %. m.p. 108-108.5 
°C (iPr2O). 
1H-NMR (CDCl3)  1.95-2.04 (m, 4H, -OCH2CH2-), 4.20 (t, 2H, -OCH2CH2-), 4.55 (t, 
2H, -CH2ONO2), 5.74 (s, 1H, OH), 6.96 (d, 1H, C6H3), 7.41-7.46 (m, 2H, C6H3), 9.85 (s, 
1H, -CHO). 13C-NMR (CDCl3)  23.7, 25.5, 68.2, 72.5, 111.0, 114.4, 124.5, 130.8, 146.1, 150.9, 
191.0. MS (CI) m/z 256 (M+1)+. 
Methyl 3-hydroxy-4-(3-nitrooxypropoxy)benzoate (27) 
The crude product was crystallized with toluene to give the title compound as a pale yellow solid; 
yield 68 %. m.p. 76.5-77 °C (toluene). 1H-NMR (CDCl3)  2.28 (qi, 2H, -OCH2CH2-), 3.88 (s, 3H, -
OCH3), 4.23 (t, 2H, -OCH2CH2-), 4.67 (t, 2H, -CH2ONO2), 5.50 (svbr, 1H, OH), 6.87 (d, 1H, 
C6H3), 7.59-7.61 (m, 2H, C6H3). 
13C-NMR (CDCl3)  26.9, 52.0, 65.0, 69.7, 110.8, 116.1, 122.8, 
123.9, 145.2, 149.2, 166.7. MS (CI) m/z 272 (M+1)+. 
Methyl 3-(morpholin-4-ylmethyl)-4-[3-(nitrooxy)propoxy]benzoate (47) 
Eluent: PE/EtOAc 60/40 v/v; colourless oil; yield: 75%. 1H-NMR (CDCl3) d 2.27 (qi, 2H, -
OCH2CH2-), 2.49 (m, 4H,-CH2NCH2-), 3.53 (s, 2H, -NCH2Ar), 3.70 (m, 4H, -CH2OCH2-), 3.89 (s, 
3H, -OCH3), 4.15 (t, 2H, -OCH2-), 4.72 (t, 2H, -CH2ONO2), 6.87 (d, 1H, C6H3), 7.94 (d, 1H, C6H3), 
8.02 (s, 1H, C6H3). 
13C-NMR (CDCl3) d 27.0, 51.9, 53.7, 56.7, 63.9, 67.0, 69.8, 110.7, 122.6, 126.1, 
130.6, 132.4, 160.4, 166.9. 
General procedure for the preparation of N-BOC-protected derivatives (9-14, 22) 
To a solution of BOC-protected aminoacid (9.38 mmol) in dry CH2Cl2 (60 mL), stirred under inert 
atmosphere, EDC.HCl (3.96 g; 20.66 mmol) and DMAP (0.12 g; 0.92 mmol) were added. After 30 
min the appropriate phenol derivative (1.70 g; 7.05 mmol) was added. The reaction was completed 
after 3 hours The reaction mixture was washed with H2O (50 mL), dried, filtered, and concentrated 
under reduced pressure. The crude product thus obtained was purified by flash chromatography. 
Chromatographic eluents and yields of the products were as follows. 
5-Formyl-2-[(nitrooxy)propoxy]-phenyl-3-[(tert-butoxycarbonyl)amino]propanoate (9) 
Eluent: PE/EtOAc 80/20 v/v; yellow solid; yield: 70 %. m.p. 80.7-83 °C (iPr2O). 
1H-NMR (CDCl3) 
 1.46 (s, 9H, t-Bu), 2.25 (qi, 2H, -OCH2CH2-), 2.84 (t, 2H, -CH2CH2NH-), 3.52-3.54 (m, 2H, -
CH2CH2NH-), 4.21 (t, 2H, -OCH2CH2-), 4.62 (t, 2H, -CH2ONO2), 5.11 (sbr, 1H, -NH), 7.08 (d, 1H, 
C6H3), 7.62 (m, 1H, C6H3), 7.75-7.79 (m, 1H, C6H3), 9.87 (s, 1H, -CHO). 
13C-NMR (CDCl3)  
26.8, 28.4, 34.5, 36.1, 64.9, 69.4, 79,7, 112.7, 123.5, 130.2, 130.4, 140.1, 154.9, 155.8, 170.0, 
189.9. MS (CI) m/z 413 (M+1)+. 
5-Formyl-2-[(nitrooxy)butoxy]-phenyl-3-[(tert-butoxycarbonyl)amino]propano (10) 
Eluent: PE/EtOAc 80/20 v/v; yellow oil; yield: 48 %. 1H-NMR (CDCl3)  1.46 (s, 9H, t-Bu), 1.89-
1.978 (m, 4H, -OCH2CH2CH2-), 2.83 (t, 2H, -CH2CH2NH-), 3.50-3.56 (m, 2H, -CH2CH2NH-), 4.13 
(t, 2H, -OCH2CH2-), 4.53 (t, 2H, -CH2ONO2), 5.02 (m, 1H, NH), 7.06 (d, 1H, C6H3), 7.61-7.62 (m, 
1H, C6H3), 7.75-7.78 (m, 1H, C6H3), 9.88 (s, 1H, -CHO). 
13C-NMR (CDCl3)  23.6, 25.3, 28.4, 
34.5, 36.2, 68.1, 72.5, 79.6, 112.7, 123.5, 130.1, 130.2, 140.1, 155.2, 155.8, 170.1, 189.9. MS (CI) 
m/z 427 (M+1)+. 
5-Formyl-2-[(nitrooxy)propoxy]-phenyl-3-[(tert-butoxycarbonyl)amino]acetate (11) 
Eluent: PE/EtOAc 80/20 v/v; white solid; yield: 50 %. m.p. 97-98 °C (iPr2O). 
1H-NMR (CDCl3)  
1.47 (s, 9H, t-Bu), 2.25 (qi, 2H, -OCH2CH2-), 4.17-4.22 (m, 4H, -CH2NH- + -OCH2CH2-), 4.64 (t, 
2H, -CH2ONO2), 5.10 (m, 1H, NH), 7.07 (d, 1H, C6H3), 7.61-7.62 (m, 1H, C6H3), 7.76-7.79 (m, 1H, 
C6H3), 9.87 (s, 1H, -CHO). 
13C-NMR (CDCl3)  26.8, 28.3, 42.1, 64.9, 69.6, 80.3, 112.7, 123.3, 
130.3, 139.9, 154.9, 155.7, 168.4, 189.8. MS (CI) m/z 399 (M+1)+. 
5-Formyl-2-[(nitrooxy)propoxy]-phenyl-3-[(tert-butoxycarbonyl)amino]butanoate (12) 
Eluent: PE/EtOAc 70/30 v/v; white solid; yield: 85 %. m.p. 71.5-72.5 °C (iPr2O). 
1H-NMR (CDCl3) 
 1.46 (s, 9H, t-Bu), 1.95 (qi, 2H, -CH2CH2NH-), 2.25 (qi, 2H, -OCH2CH2-), 2.66 (t, 2H, -
COCH2CH2-), 3.23-3.30 (m, 2H, -CH2CH2NH-), 4.20 (t, 2H, -OCH2CH2-), 4.62 (t, 2H, -
CH2ONO2), 4.70 (sbr, 1H, NH), 7.07 (d, 1H, C6H3), 7.60-7.61 (m, 1H, C6H3), 7.75-7.78 (m, 1H, 
C6H3), 9.88 (s, 1H, -CHO). 
13C-NMR (CDCl3)  25.4, 26.8, 28.4, 31.1, 39.8, 64.8, 69.5, 79.4, 112.7, 
123.6, 130.1, 130.3, 140.2, 155.0, 156.0, 170.9, 190.0. MS (CI) m/z 427 (M+1)+. 
5-Formyl-2-[(nitrooxy)propoxy]-phenyl-2-[(tert-butoxycarbonyl)amino]propanoate (13) 
Eluent: PE/EtOAc 70/30 v/v; white solid; yield: 65 %. 93.5 °C darkening/fuming, m.p. 102 
°C(iPr2O). 
1H-NMR (CDCl3) 1.47 (s, 9H, t-Bu), 1.57 (d, 3H, -CHCH3), 2.24 (qi, 2H, -OCH2CH2-), 
4.19 (t, 2H, -OCH2CH2-), 4.58-4.66 (m, 3H, -CHCH3 + -CH2ONO2), 5.05-5.08 (m, 1H, NH), 7.07 
(d, 1H, C6H3), 7.61-7.62 (m, 1H, C6H3), 7.76-7.79 (m, 1H, C6H3), 9.88 (s, 1H, -CHO). 
13C-NMR 
(CDCl3)  18.5, 26.8, 28.3, 49.2, 64.7, 69.4, 80.1, 110.7, 112.7, 123.4, 130.3, 140.0, 155.0, 171.2, 
189.8. MS (CI) m/z 413 (M+1)+. 
5-Formyl-2-[(nitrooxypropoxy)-phenyl-2-(tert-butoxycarbonylamino)-3-(tert-butyl-
dimethylsyliloxy)butanoate (14) 
Eluent: PE/EtOAc 90/10 v/v; colourless oil; yield: 29 %. 1H-NMR (CDCl3)  0.11 (s, 3H, CH3Si-), 
0.12 (s, 3H, CH3Si-), 0.90 (s, 9H, tBuSi-), 1.31 (s, 3H, -CHCH3), 1.47 (s, 9H, tBuO-), 2.25 (q, 2H, -
OCH2CH2-), 4.16 (t, 2H, -OCH2CH2-), 4.45-4.49 (m, 1H, -CHNH-), 4.60-4.72 (m, 3H, -CH2ONO2 
+ -CHOSi-), 5.25-5.30 (m, 1H, -NH-), 7.07 (d, 1H, C6H3), 7.60-7.61 (m, 1H, C6H3), 7.74-7.78 (m, 
1H, C6H3), 9.87 (s, 1H, -CHO). 
13C-NMR (CDCl3)  -4.9, -4.1, 18.0, 21.0, 25.7, 26.7, 28.3, 59.5, 
64.7, 68.7, 69.6, 80.0, 112.8, 122.8, 130.2, 140.4, 155.0, 156.1, 169.2, 189.8. 
2-(Allyloxy)-5-formylphenyl 3-[(tert-butoxycarbonyl)amino]propanoate (22) 
Eluent: PE/EtOAc 90/10 v/v to 80/20; colourless oil; yield: 56 %. 1H-NMR (CDCl3)  1.46 (s, 9H, 
t-Bu), 2.82 (t, 2H, -CH2CH2NH-), 3.53-3.58 (m, 2H, -CH2CH2NH-), 4.67-4.68 (m, 2H, -OCH2-), 
5.17 (svbr, 1H, -NH), 5.32-5.43 (m, AMX like system, 2H, -CH=CH2), 5.95-6.08 (m, AMX like 
system, 1H, -CH=CH2), 7.07 (d, 1H, C6H3), 7.61-7.62 (m, 1H, C6H3), 7.73-7.76 (m, 1H, C6H3), 9.87 
(s, 1H, -CHO). 13C-NMR (CDCl3)  28.4, 31.1, 33.8, 34.7, 36.2, 69.6, 79.5, 113.2, 118.9, 123.5, 
130.1, 131.6, 140.2, 155.0, 190.0. MS (CI) m/z 350 (M+1)+. 
2-[2,3-Bis(nitrooxy)propyl]-5-formylphenyl 3-[(tert-butoxycarbonyl)amino]propanoate (23) 
Iodine (0.70 g, 2.78 mmol) was added portionwise to a stirred solution of 22 (0.97g, 2.78 mmol) 
plus AgNO3 (0.47 g, 2.78 mmol) in CH3CN (10 mL) kept at -15 °C. At the end of the addition, 
stirring was continued for 1h. AgNO3 (1.18 g, 6.95 mmol) was then added and the mixture heated to 
70 °C for 16 h. After cooling, the mixture was filtered through Celite. The filtrate was 
concentrated under reduced pressure, dissolved in water (40 mL) and extracted with EtOAc (3 x 20 
mL). The combined organic layers were washed with brine (20 mL), dried with MgSO4, filtered, 
and concentrated under reduced pressure. The crude product was purified by flash chromatography 
(PE/EtOAc 80/20 v/v) to give the title compound as a yellow oil; yield: 31 %. 1H-NMR (CDCl3)  
1.46 (s, 9H, t-Bu), 2.84 (t, 2H, -CH2CH2NH-), 3.51-3.56 (m, 2H, -CH2CH2NH-), 4.38 (d, 2H, -
OCH2CH-), 4.69-4.90 (m, AMX-like system, 2H, -CHCH2ONO2), 5.03 (svbr, 1H, -NH), 5.62-5.66 
(m, AMX-like system, 1H, -CHCH2ONO2), 7.08 (d, 1H, C6H3), 7.64-7.65 (m, 1H, C6H3), 7.76-7.81 
(m, 1H, C6H3), 9.90 (s, 1H, -CHO). 
13C-NMR (CDCl3)  14.2, 27.9, 28.4, 34.5, 36.0, 60.5, 65.8, 
68.4, 70.0, 113.0, 123.9, 130.0, 131.3, 140.2, 153.9, 155.9, 179.9, 189.8. MS (CI) m/z 473 (M+1)+. 
General procedure for the preparation of carboxylic acid from aldehyde (15-20, 24) 
KMnO4 (0.52 g, 3.27 mmol) was added to a solution of the appropriate aldehyde (2.18 mmol) in 
acetone (50 mL), and stirred at 0 °C. The reaction was allowed to reach r.t.; it was complete after 1h 
(TLC detection, eluent CH2Cl2/MeOH 95/5 v/v). Oxalic acid was added and the mixture was 
filtered and the filtrate was diluted with CH2Cl2 (100 mL). The organic layer was washed twice 
with H2O (50 mL), then dried with MgSO4, filtered, and concentrated under reduced pressure to 
give the desired product. 
3-({3-[(tert-Butoxycarbonyl)amino]propanoyl}oxy)-4-[(nitrooxy)propoxy]benzoic acid (15) 
White solid; yield 96 %. m.p. 123-126 °C (Toluene). 1H-NMR (DMSO-d6)  1.46 (s, 9H, t-Bu), 
2.15 (qi, 2H, -OCH2CH2-), 2.73 (t, 2H, -CH2CH2NH-), 3.10-3.17 (m, 2H, -CH2CH2NH-), 4.17 (t, 
2H, -OCH2CH2-), 4.61 (t, 2H, -CH2ONO2), 6.97-5.00 (m, 1H, -NH), 7.23 (d, 1H, C6H3), 7.70 (m, 
1H, C6H3), 7.83-7.87 (m, 1H, C6H3), 12.8 (svvbr, 1H, -COOH). 
13C-NMR (DMSO-d6)  26.0, 28.1, 
33.9, 36.0, 64.9, 70.5, 77.8, 113.0, 123.3, 124.0, 128.7, 138.9, 153.5, 155.5, 166.3, 169.3. MS (CI) 
m/z 429 (M+1)+. 
3-({3-[(tert-Butoxycarbonyl)amino]propanoyl}oxy)-4-[(nitrooxy)butoxy]benzoic acid (16) 
White solid; yield 90 %. m.p. 102 °C (toluene). 1H-NMR (DMSO-d6)  1.39 (s, 9H, t-Bu), 1.79-
1.83 (m, 4H, -OCH2CH2CH2-), 2.71 (t, 3H, -CH2CH2NH-), 3.26-3.33 (m, 2H, -CH2CH2NH-), 4.11 
(t, 2H, -OCH2CH2-), 4.57 (t, 2H, -CH2ONO2), 6.97-7.01 (m, 1H, NH), 7.21 (d, 1H, C6H3), 7.67-
7.68 (m, 1H, C6H3), 7.82-7.85 (d, 1H, C6H3), 12.8 (sbr, 1H, -COOH). 
13C-NMR (DMSO-d6)  22.7, 
24.6, 28.1, 33.9, 36.0, 67.7, 73.3, 77.7, 113.0, 123.0, 123.9, 128.7, 138.8, 153.7, 155.4, 166.3, 
169.2. MS (CI) m/z 443 (M+1)+. 
3-({3-[(tert-Butoxycarbonyl)amino]acetoxy})-4-[(nitrooxy)propoxy]benzoic acid (17) 
White solid; yield 50 %. m.p. 158.5-159 °C (Toluene). 1H-NMR (DMSO-d6)  1.40 (s, 9H, t-Bu), 
2.09-2.16 (m, 2H, -OCH2CH2-), 3.99-4.01 (m, 2H, -CH2NH-), 4.16 (t, 2H, -OCH2CH2-), 4.66 (t, 
2H, -CH2ONO2), 7.26 (d, 1H, C6H3), 7.61-7.62 (m, 1H, C6H3), 7.84-7.87 (m, 1H, C6H3), 12.0 (sbr, 
1H, -COOH). 13C-NMR (DMSO-d6)  26.9, 28.9, 42.5, 65.7, 71.5, 79.3, 114.1, 124.2, 124.4, 129.8, 
139.7, 154.4, 156.7, 167.1, 169.6. MS (CI) m/z 415 (M+1)+. 
3-({3-[(tert-Butoxycarbonyl)amino]butanoyl}oxy)-4-[(nitrooxy)propoxy]benzoic acid (18) 
White solid; yield 75 %. m.p. 138-140 °C (Toluene). 1H-NMR (CDCl3)  1.46 (s, 9H, t-Bu), 1.95 
(qi, 2H, -CH2CH2NH-), 2.23 (qi, 2H, -OCH2CH2-), 2.66 (t, 2H, -COCH2CH2-), 3.24-3.30 (m, 2H, -
CH2CH2NH-), 4.18 (t, 2H, -OCH2CH2-), 4.61 (t, 2H, -CH2ONO2), 4.70 (sbr, 1H, NH), 6.99 (d, 1H, 
C6H3), 7.79 (s, 1H, C6H3), 8.00 (d, 1H, C6H3). 
13C-NMR (CDCl3)  25.4, 26.8, 28.4, 29.7, 31.1, 
64.6, 69.5, 82.3, 112.3, 122.4, 125.1, 129.8, 139.4, 154.4, 169.6, 170.9. MS (CI) m/z 443 (M+1)+. 
3-({2-[(tert-Butoxycarbonyl)amino]propanoyl}oxy)-4-[(nitrooxy)propoxy]benzoic acid (19) 
White solid; yield 80 %. m.p. 133-134 °C (Toluene). 1H-NMR (DMSO-d6)  
1H-NMR (CDCl3)  
1.41-1.43 (m, 12H, t-Bu + -CHCH3), 2.13 (qi, 2H, -OCH2CH2-), 4.16 (t, 2H, -OCH2CH2-), 4.24-
4.30 (m, 1H, -CHCH3), 4.65 (t, 2H, -CH2ONO2), 7.25 (d, 1H, C6H3), 7.51-7.57 (m, 2H, C6H3 + 
NH), 7.84-7.87 (m, 1H, C6H3), 12.91 (sbr, 1H, -COOH). 
13C-NMR (DMSO-d6)  16.6, 25.9, 28.1, 
49.0, 64.7, 70.4, 78.3, 113.0, 123.3, 123.5, 128.8, 138.7, 153.5, 155.2, 166.2, 171.3. MS (CI) m/z 
429 (M+1)+. 
3-[3-(tert-butoxycarbonylamino)(tert-butyl-dimethylsyliloxy)butoxy]-4-
(nitrooxypropoxy)benzoic acid (20) 
Colourless oil; yield 71 %. 1H-NMR (CDCl3)  0.12 (s, 3H, CH3Si-), 0.13 (s, 3H, CH3Si-), 0.84 (s, 
9H, tBuSi-), 1.35 (d, 3H, -CHCH3), 1.48 (s, 9H, tBuO-), 2.22 (qi, 2H, -OCH2CH2-), 4.16 (t, 2H, -
OCH2CH2-), 4.48-4.52 (m, 1H, -CHNH-), 4.61-4.69 (m, 3H, -CH2ONO2 + -CHOSi-), 5.31 (d, 1H, -
NH-), 6.99 (d, 1H, C6H3), 7.81-7.82 (m, 1H, C6H3), 7.98-8.02 (m, 1H, C6H3), 9.86 (sbr, 1H, -CHO). 
13C-NMR (CDCl3)  -4.9, -4.1, 18.4, 21.0, 25.7, 26.7, 28.3, 59.5, 64.6, 68.7, 69.7, 80.0, 112.4, 
122.4, 124.5, 130.0, 139.5, 154.4, 156.1, 169.2, 170.6. MS (CI) m/z 574 (M+1)+. 
4-[2,3-bis(nitrooxy)propyl]-3-({3-[(tert-butoxycarbonyl)amino]propanoyl}oxy)benzoic acid 
(24) 
Pale yellow oil; yield 90 %. 1H-NMR (DMSO-d6)  1.36 (s, 9H, t-Bu), 2.70 (q, 2H, -CH2CH2NH-), 
4.41-4.49 (m, 2H, -OCH2CH-), 4.81-5.01 (m, AMX like system, 2H, -CHCH2ONO2), 5.75-5.85 (m, 
AMX-like system, 1H, -CHCH2ONO2), 6.98 (t, 1H, -NH), 7.24 (d, 1H, C6H3), 7.38 (sbr, 1H, -
COOH), 7.69-7.70 (m, 1H, C6H3), 7.81-7.85 (m, 1H, C6H3). 
13C-NMR (DMSO-d6)  29.3, 35.0, 
36.9, 50.7, 66.8, 70.5, 78.4, 114.2, 116.2, 125.1, 129.6, 139.8, 153.7, 163.4, 167.1, 169.6. MS (CI) 
m/z 490 (M+1)+. 
3-Hydroxy-4-(3-nitrooxypropoxy)benzoic acid (28) 
To a solution of 27 (0.56 g, 2.06 mmol) in THF (10 mL) and H2O (10 mL), NaOH pellets (165 mg; 
4.13 mmol) were added. The mixture was heated to 40 °C for 4 h. The residue was treated with 
EtOAc (10 mL) and H2O (10 mL). After separation, the aqueous layer was acidified with HCl 6N 
and extracted twice with EtOAc (20 mL). The combined organic layers were dried with MgSO4, 
filtered, and concentrated under reduced pressure to give the title compound as a yellow solid; yield 
59 %. m.p. 166.5-169.5 °C (toluene). 1H-NMR (DMSO-d6)  2.14 (qi, 2H, -OCH2CH2-), 4.12 (t, 
2H, -OCH2CH2-), 4.74 (t, 2H, -CH2ONO2), 7.00 (d, 1H, C6H3), 7.35-7.42 (m, 2H, C6H3), 9.27 
(svbr, 1H, OH), 12.58 (svbr, 1H, -COOH). 13C-NMR (DMSO-d6)  26.0, 64.4, 70.8, 112.4, 116.1, 
121.4, 123.4, 146.2, 150.4, 167.0. MS (CI) m/z 258 (M+1)+. 
3-(Morpholin-4-ylmethyl)-4-[3-(nitrooxy)propoxy]benzoic acid (48) 
A solution of 29 (0.56 mmol) in MeOH (5 mL) and 1N NaOH (2 mL) was stirred at room 
temperature for 4 h. The solvent was then removed under reduced pressure, the residue dissolved in 
H2O (10 mL), the pH adjusted to 7, and the product extracted in continuous cycle for 18 h with 
EtOAc. The EtOAc layer was dried with MgSO4, filtered, and concentrated under reduced pressure 
to give the desired compound. Colourless oil; yield: 67%. 1H-NMR (CDCl3)  2.28 (qi, 2H, -
OCH2CH2-), 2.79 (m, 4H, -CH2NCH2-), 3.77 (m, 4H, -CH2OCH2-), 3.85 (s, 2H, -NCH2Ar), 4.21 (t, 
2H, -OCH2-), 4.74 (m, 2H, -CH2ONO2), 7.07 (d, 1H, C6H3), 7.98 (d, 1H, C6H3), 8.04 (s, 1H, C6H3). 
13C-NMR (CDCl3)  28.0, 54.2, 57.1, 66.1, 66.9, 71.9, 112.2, 123.7, 126.4, 133.0, 134.7, 161.8, 
171.0. 
General procedure for the preparation of aspirin esters (30-37, 49) 
To a solution of 29 (0.58 g, 2.52 mmol) in DMF (8 mL) the appropriate carboxylic acid derivative 
(2.52 mmol) and Cs2CO3 (0.41 g, 1.26 mmol) were added. The mixture was stirred at room 
temperature for 24 hours, then poured into H2O (30 mL) and extracted with EtOAc (3 × 5 mL). The 
combined organic layers were dried with MgSO4, filtered, and concentrated under reduced pressure. 
The crude product thus obtained was purified by flash chromatography. Chromatographic eluents 
and yields of the products were as follows. 
{[2-(Acetyloxy)benzoyl]oxy}methyl 3-({3-[tert-butoxycarbonyl)amino]propanoyl}oxy-4-[3-
(nitrooxy)propoxy]benzoate (30) 
Eluent: PE/EtOAc 90/10 to 70/30 v/v; colourless oil; yield: 70 %. 1H-NMR (CDCl3)  1.45 (s, 9H, 
t-Bu), 2.23 (qi, 2H, -OCH2CH2-), 2.35 (s, 3H, CH3CO-), 2.82 (t, 2H, -CH2CH2NH-), 3.49-3.55 (m, 
2H, -CH2CH2NH-), 4.18 (t, 2H, -OCH2CH2-), 4.60 (t, 2H, -CH2ONO2), 5.06 (m, 1H, -NH), 6.16 (s, 
2H, -OCH2O-), 6.99 (d, 1H, C6H3), 7.11 (d, 1H, C6H4), 7.33 (t, 1H, C6H4), 7.60 (t, 1H, C6H4), 7.79-
7.80 (m, 1H, C6H3), 7.98-8.01 (m, 1H, C6H3), 8.07-8.10 (m, 1H, C6H4). 
13C-NMR (CDCl3)  21.0, 
26.8, 28.4, 34.5, 36.0, 64.7, 69.4, 79.6, 79.8, 112.4, 121.9, 122.0, 124.0, 124.9, 126.2, 129.9, 132.3, 
134.7, 139.2, 151.1, 154.3, 155.7, 163.1, 164.0, 169.7, 171.2. MS (CI) m/z 621 (M+1)+. 
{[2-(Acetyloxy)benzoyl]oxy}methyl-3-({3-[tert-butoxycarbonyl)amino]propanoyl}oxy-4-[3-
(nitrooxy)butoxy]benzoate (31) 
Eluent: PE/EtOAc 90/10 to 70/30 v/v; colourless oil; yield: 45 %. 1H-NMR (CDCl3)  1.45 (s, 9H, 
t-Bu), 1.82-2.03 (m, 4H, -OCH2CH2CH2-), 2.35 (s, 3H, CH3CO-), 2.81 (t, 2H, -CH2CH2NH-), 3.52 
(q, 2H, -CH2CH2NH-), 4.11 (t, 2H, -OCH2CH2-), 4.51 (t, 2H, -CH2ONO2), 5.05-5.15 (m, 1H, NH), 
6.16 (s, 2H, -OCH2O-), 6.98 (d, 1H, C6H3), 7.11 (d, 1H, C6H4), 7.32 (t, 1H, C6H4), 7.60 (t, 1H, 
C6H4), 7.79-7.80 (m, 1H, C6H3) 7.97-8.00 (m, 1H, C6H3), 8.07-8.10 (m, 1H, C6H4). 
13C-NMR 
(CDCl3)  21.0, 23.6, 25.2, 28.4, 34.5, 36.1, 67.9, 72.5, 79.8, 112.3, 121.6, 122.0, 124.0, 124.8, 




Eluent: PE/EtOAc 80/20 to 60/40 v/v; colourless oil; yield: 70 %. 1H-NMR (CDCl3)  1.46 (s, 9H, 
t-Bu), 2.23 (qi, 2H, -OCH2CH2-), 2.35 (s, 3H, CH3CO-), 4.11-4.20 (m, 4H, -CH2NH- + -OCH2CH2-
), 4.63 (t, 2H, -CH2ONO2), 5.06 (sbr, 1H, NH), 6.16 (s, 2H, -OCH2O-), 6.98 (d, 1H, C6H3), 7.11 (d, 
1H, C6H4), 7.32 (t, 1H, C6H4), 7.60 (t, 1H, C6H4), 7.80 (m, 1H, C6H3), 7.98-8.01 (m, 1H, C6H3), 
8.07-8.09 (m, 1H, C6H4). 
13C-NMR (CDCl3)  21.0, 26.9, 28.3, 42.1, 64.6, 69.7, 76.6, 79.8, 85.4, 
112.4, 121.9, 124.0, 124.7, 126.1, 130.0, 132.3, 134.6, 139.1, 151.1, 154.4, 155.7, 163.1, 164.0, 
168.3, 169.7, 189.8. MS (CI) m/z 607 (M+1)+. 
{[2-(Acetyloxy)benzoyl]oxy}methyl-3-({3-[tert-butoxycarbonyl)amino]butanoyl}oxy-4-[3-
(nitrooxy)propoxy]benzoate (33) 
Eluent: PE/EtOAc 80/20 to 60/40 v/v; colourless oil; yield: 72 %. 1H-NMR (CDCl3)  1.45 (s, 9H, 
t-Bu), 1.93 (qi, 2H, -CH2CH2NH-), 2.25 (qi, 2H, -OCH2CH2-), 2.35 (s, 3H, CH3CO-), 2.64 (t, 2H, -
COCH2CH2-), 3.22-3.28 (m, 2H, -CH2CH2NH-), 3.56 (sbr, 1H, NH), 4.17 (t, 2H, -OCH2CH2-), 4.60 
(t, 2H, -CH2ONO2), 6.16 (s, 2H, -OCH2O-), 6.98 (d, 1H, C6H3), 7.11 (d, 1H, C6H4), 7.32 (t, 1H, 
C6H4), 7.57-7.62 (m, 1H, C6H4), 7.77-7.78 (m, 1H, C6H3), 7.96-8.00 (m, 1H, C6H3), 8.06-8.10 (m, 
1H, C6H4). 
13C-NMR (CDCl3)  21.0, 25.4, 26.8, 28.4, 31.1, 39.8, 64.7, 69.5, 79.4, 79.9, 112.4, 
122.0, 122.1, 124.0, 125.0, 126.1, 129.8, 132.2, 134.7, 139.5, 151.1, 154.5, 156.0, 163.1, 164.1, 
169.7, 170.8. MS (CI) m/z 635 (M+1)+. 
{[2-(Acetyloxy)benzoyl]oxy}methyl-3-({2-[tert-butoxycarbonyl)amino]propanoyl}oxy-4-[3-
(nitrooxy)propoxy]benzoate (34) 
Eluent: PE/EtOAc 80/20 to 70/30 v/v; colourless oil; yield: 50 %. 1H-NMR (CDCl3)  1.41-1.43 (s, 
19H, t-Bu), 1.57 (d, 3H, -CHCH3), 2.21 (qi, 2H, -OCH2CH2-), 2.35 (s, 3H, CH3CO-), 4.16 (t, 2H, -
OCH2CH2-), 4.60-4.64 (m, 3H, -CH2ONO2 + -CHCH3), 5.03-5.07 (m, 1H, NH), 6.16 (s, 2H, -
OCH2O-), 6.98 (d, 1H, C6H3), 7.11 (d, 1H, C6H4), 7.32 (t, 2H, C6H4), 7.59 (t, 1H, C6H4), 7.79-7.80 
(m, 1H, C6H3), 7.98-8.01 (m, 1H, C6H3), 8.07-8.10 7.79-7.80 (m, 1H, C6H4). 
13C-NMR (CDCl3)  
18.6, 21.0, 26.7, 28.3, 64.6, 69.5, 79.8, 112.4, 121.9, 122.0, 124.0, 124.7, 126.1, 130.0, 132.3, 
134.7, 139.2, 151.1, 154.4, 163.0, 164.0, 169.7, 171.2. MS (CI) m/z 621 (M+1)+. 
{[2-(Acetyloxy)benzoyl]oxy}methyl-3-({3-[tert-butoxycarbonyl)amino](tert-butyl-
dimethylsyliloxy)butoxy)-4-(3-nitrooxypropoxy)benzoate (35) 
Eluent: PE/EtOAc 70/30 v/v; colourless oil; yield: 35 %. 1H-NMR (CDCl3)  0.09 (s, 3H, CH3Si-), 
0.10 (s, 3H, CH3Si-), 0.88 (s, 9H, tBuSi-), 1.32 (d, 3H, -CHCH3), 1.46 (s, 9H, tBuO-), 2.18 (qi, 2H, 
-OCH2CH2-), 2.32 (s, 3H, CH3CO-), 4.13 (t, 2H, -OCH2CH2-), 4.44-4.47 (m, 1H, -CHNH-), 4.60-
4.67 (m, 3H, -CH2ONO2 + -CHOSi-), 5.24 (d, 1H, -NH-), 6.15 (s, 2H, -OCH2O-), 6.97 (d, 1H, 
C6H3), 7.10 (d, 1H, C6H4), 7.30 (t, 1H, C6H4), 7.54-7.60 (m, 1H, C6H4), 7.69-7.70 (m, 1H, C6H3), 
7.95-7.99 (m, 1H, C6H3), 8.04-8.07 (m, 1H, C6H4). 
13C-NMR (CDCl3)  -4.9, -4.1, 18.0, 20.9, 25.8, 
26.9, 28.4, 59.7, 64.9, 68.8, 69.7, 80.1, 112.7, 122.0, 122.3, 124.1, 124.6, 126.1, 129.8, 132.2, 
134.6, 139.8, 151.2, 154.6, 156.1, 163.0, 164.0, 169.1, 169.4. 
{[2-(Acetyloxy)benzoyl]oxy}methyl-3-({3-[tert-butoxycarbonyl)amino]propanoyl}oxy-4-
[2,3bis(nitrooxy)propoxy]benzoate (36) 
Eluent: PE/EtOAc 80/20 to 60/40 v/v; colourless oil; yield: 47 %. 1H-NMR (CDCl3)  1.45 (s, 9H, 
t-Bu), 2.34 (s, 3H, CH3CO-), 2.82 (t, 2H, -CH2CH2NH-), 3.50-3.53 (m, 2H, -CH2CH2NH-), 4.30 (d, 
2H, -OCH2CH-), 4.65-4.86 (m, AMX-like system, 2H, -CHCH2ONO2), 5.09 (svbr, 1H, -NH), 5.59-
.62 (m, 1H, -CHCH2ONO2), 6.16 (s, 2H, -OCH2O-), 6.97 (d, 1H, C6H3), 7.11 (d, 1H, C6H4), 7.32 (t, 
1H, C6H4), 7.59 (t, 1H, C6H4), 7.80-7.81 (m, 1H, C6H3), 7.96-8.00 (m, 1H, C6H3), 8.07 (d, 1H, 
C6H4). 
13C-NMR (CDCl3)  21.0, 28.3, 31.2, 34.4, 65.6, 68.5, 76.1, 79.6, 79.9, 110.7, 121.9, 123.1, 
124.0, 125.2, 126.2, 129.8, 132.2, 134.8, 139.4, 151.1, 153.4, 155.8, 163.1, 163.8, 169.7, 170.0. MS 
(CI) m/z 682 (M+1)+. 
{[2-(Acetyloxy)benzoyl]oxy}methyl- 3-hydroxy-4-(3-nitrooxypropoxy)benzoate (37) 
Eluent: PE/EtOAc 90/10 to 70/30 v/v; white solid; yield: 37 %. m.p.: 84.5-85.5 °C. 1H-NMR 
(CDCl3)  2.26 (qi, 2H, -OCH2CH2-), 2.35 (s, 3H, CH3CO-), 4.22 (t, 2H, OCH2CH2-), 4.65 (t, 2H, -
CH2ONO2), 5.62 (s, 1H, OH), 6.16 (s, 2H, -OCH2O-), 6.85 (d, 1H, C6H3), 7.12 (d, 1H, C6H4), 7.32 
(t, 1H, C6H4), 7.56-7.67 (m, 3H, C6H3 + C6H4), 8.07-8.10 (m, 1H, C6H4). 
13C-NMR (CDCl3)  21.0, 
26.9, 65.1, 69.6, 79.8, 110.8, 116.5, 122.1, 122.5, 123.5, 124.0, 126.1, 132.3, 134.6, 145.4, 149.8, 
151.0, 163.1, 164.7, 169.8. MS (CI) m/z 450 (M+1)+. 
{[2-(Acetyloxy)benzoyl]oxy}methyl 3-(morpholin-4-ylmethyl)-4-[3-
(nitrooxy)propoxy]benzoate oxalate (49) 
The crude product was purified by flash chromatography (PE/EtOAc 60/40 v/v) to give {[2-
(acetyloxy)benzoyl]oxy}methyl 4-(morpholin-4-ylmethyl)-3-[3-(nitrooxy)propoxy]benzoate (0.38 
g) as a colourless oil. To a solution of {[2-(acetyloxy)benzoyl]oxy}methyl 4-(morpholin-4-
ylmethyl)-3-[3-(nitrooxy)propoxy]benzoate in EtOAc (3 mL) was added a solution of H2C2O4 (0.06 
g, 1 eq) in EtOAc (2 mL) and the title compound (0.17 g) was obtained by filtration as a white 
solid; yield: 20%. m.p. 135-139 °C (dec.). 1H-NMR (DMSO-d6)  2.17-2.25 (m, 5H, -OCH2CH2- + 
-COCH3), 2.71 (m, 4H, -CH2NCH2-), 3.64 (m, 4H, -CH2OCH2-), 3.83 (s, 2H, -NCH2Ar), 4.20 (t, 
2H, -OCH2-), 4.74 (t, 2H, -CH2ONO2), 6.14 (s, 2H, -OCH2O-), 7.19 (d, 1H, Arom), 7.27 (d, 1H, 
Arom), 7.42 (t, 1H, Arom), 7.73 (t, 1H, Arom), 7.96-8.05 (m, 3H, Arom), 8.06 (s, 1H, Arom). 13C-
NMR (DMSO-d6)  20.9, 26.3, 52.7, 54.9, 65.2, 65.3, 71.3, 80.5, 112.2, 120.5, 122.2, 124.5, 126.7, 
131.8, 132.1, 133.2, 135.4, 150.5, 161.6, 162.6, 163.1, 164.3, 169.3. 
General procedure for the preparation of aminoacid derivatives (38-44) 
A solution of the appropriate BOC-protected intermediate (2.00 mmol) in dry dioxane HCl 2.36 M 
(12.6 mL, 29.0 mmol), was stirred under inert atmosphere for 3 h. The mixture was concentrated 
under reduced pressure. 
Hydrochloridric salt of {[2-(acetyloxy)benzoyl]oxy}methyl-3-[(3-[aminopropanoyl)oxy]-4-[3-
(nitrooxy)propoxy]benzoate (38) 
The crude product was tritured with dry Et2O to give the title compound as a white solid; yield: 89 
%. m.p.: 94.5-95.5 °C. 1H-NMR (DMSO-d6)  2.16 (qi, 2H, -OCH2CH2-), 2.25 (s, 3H, CH3CO-), 
3.01-3.06 (m, 2H, -CH2CH2NH2), 3.11-3.13 (m, 2H, -CH2CH2NH2), 4.21 (t, 2H, -OCH2CH2-), 4,63 
(t, 2H, -CH2ONO2), 6.14 (s, 2H, -OCH2O-), 7.26-7.34 (m, 2H, C6H3 + C6H4), 7.44 (t, 1H, C6H4), 
7.71-7.77 (m, 1H, C6H4), 7.82-7.83 (m, 1H, C6H3), 7.93-8.00 (m, 2H, C6H3 + C6H4), 8.22 (svvbr, 
2H, -NH2). 
13C-NMR (CDCl3)  21.0, 26.6, 31.0, 35.5, 65.0, 70.1, 80.0, 112.4, 121.7, 122.0, 124.0, 
124.8, 126.2, 129.9, 132.3, 134.7, 139.1, 151.0, 154.4, 163.1, 164.1, 169.0, 169.7. 
Hydrochloridric salt of {[2-(acetyloxy)benzoyl]oxy}methyl-3-[(3-[aminopropanoyl)oxy]-4-[3-
(nitrooxy)butoxy]benzoate (39) 
The crude product was purified by flash chromatography (H2O/CH3CN/HCl 60/40/0.1 v/v/v) to 
give the title compound as a colourless oil; yield: 50 %. 1H-NMR (DMSO-d6 + CDCl3)  1.78-1.94 
(m, 4H, -OCH2CH2CH2-), 2.28 (s, 3H, CH3CO-), 3.09 (t, 2H, -CH2CH2NH-), 3.21 (t, 2H, -
CH2CH2NH-), 4.13 (t, 2H, -OCH2CH2-), 4.58 (t, 2H, -CH2ONO2), 6.14 (s, 2H, -OCH2O-), 7.17-
7.21 (m, 2H, C6H3 + C6H4), 7.42 (t, 1H, C6H4), 7.81 (t, 1H, C6H4), 7.79-7.80 (m, 1H, C6H3), 7.94-
8.03 (m, 2H, C6H3 + C6H4), 8.34 (svvbr, 2H, NH2). 
13C-NMR (DMSO-d6 + CDCl3)  21.4, 23.8, 
25.5, 31.9, 35.4, 68.7, 73.8, 80.6, 113.7, 121.4, 122.7, 124.7, 125.0, 126.9, 130.3, 132.3, 135.5, 
139.6, 151.2, 155.4, 163.5, 164.3, 169.0, 169.7. 
Hydrochloridric salt of {[2-(acetyloxy)benzoyl]oxy}methyl-3-[(2-amino)acetoxy]-4-[3-
(nitrooxy)propoxy]benzoate (40) 
The crude product was tritured with dry Et2O to give the title compound as a white solid; yield: 40 
%. m.p.: 60.5-62.5 °C. 1H-NMR (CDCl3)  2.16 (m, 2H, -OCH2CH2-), 2.31 (s, 3H, CH3CO-), 3.99 
(m, 2H,), 4.20 (t, 2H) (-CH2NH2 + OCH2CH2-), 4.53 (t, 2H, -CH2ONO2), 6.16 (s, 2H, -OCH2O-), 
6.83 (d, 1H, C6H3), 7.08 (d, 1H, C6H4), 7.27 (t, 1H, C6H4), 7.55 (t, 1H, C6H4), 7.71 (s, 1H, C6H3), 
7.86 (d, 1H, C6H3), 8.03 (d, 1H, C6H4), 8.69 (svvbr, 3H, NH3
+).13C-NMR (CDCl3)  20.9, 26.5, 
40.4, 65.2, 70.5, 79.9, 112.5, 121.5, 122.0, 124.0, 124.3, 126.2, 130.2, 132.2, 134.7, 138.5, 151.0, 
154.2, 158.4, 163.0, 163.9, 165.7, 169.7. 
Hydrochloridric salt of {[2-(acetyloxy)benzoyl]oxy}methyl-3-[(4-amino)butanoyl]oxy-4-[3-
(nitrooxy)propoxy]benzoate (41) 
The crude product was purified by flash chromatography (H2O/CH3CN/HCl 70/30/0.1 v/v/v) to 
give the title compound as a colourless oil; yield: 42 %. 1H-NMR (CDCl3)  2.14-2.18 (m, 4H, -
OCH2CH2- + -CH2CH2NH2), 2.32 (s, 3H, CH3CO-), 2.74 (t, 2H, COCH2CH2-), 3.10-3.20 (m, 2H, -
CH2CH2NH2), 4.07 (t, 2H, -OCH2CH2-), 4.56 (t, 2H, -CH2ONO2), 6.12 (s, 2H, -OCH2O-), 6.90 (d, 
1H, C6H3), 7.09 (d, 1H, C6H4), 7.29 (t, 1H, C6H4), 7.56 (t, 1H, C6H4), 7.75-7.76 (m, 1H, C6H3), 
7.90-7.94 (m, 1H, C6H3), 8.02-8.06 (m, 1H, C6H4), 8.30 (svvbr, 3H, NH3
+).13C-NMR (CDCl3)  
21.0, 22.6, 26.7, 30.6, 39.2, 65.0, 70.0, 79.9, 112.4, 121.7, 122.0, 124.0, 124.8, 126.2, 129.8, 132.2, 
134.7, 139.4, 151.0, 154.5, 163.1, 164.1. 169.7, 170.4. 
Hydrochloridric salt of {[2-(acetyloxy)benzoyl]oxy}methyl-3-[(2-amino)propanoyl]oxy-4-[3-
(nitrooxy)propoxy]benzoate (42) 
The crude product was purified by flash chromatography (H2O/CH3CN/HCl 80/20/0.1 v/v/v to 
60/40/0.1 v/v/v) to give the title compound as a white solid; yield: 44 %. m.p.: 65.5-69.0 °C. 1H-
NMR (CDCl3)  1.78 (d, 3H, -CHCH3), 2.09-2.11 (m, 2H, -OCH2CH2-), 2.32 (s, 3H, CH3CO-), 
4.03 (m, 2H, -OCH2CH2-), 4.40 (m, 1H, -CHCH3), 4.53 (t, 2H, -CH2ONO2), 6.12 (s, 
2H, -OCH2O-), 6.84 (d, 1H, C6H3), 7.10 (d, 1H, C6H4), 7.29 (t, 1H, C6H4), 7.65 (t, 1H, C6H4), 7.75 
(s, 1H, C6H3), 7.86 (d, 1H, C6H3), 8.02 (d, 1H, C6H4), 8.84 (svvbr, 3H, NH3
+). 13C-NMR (CDCl3)  
16.1, 21.0, 26.6, 65.1, 70.1, 79.9, 112.4, 121.6, 122.0, 124.0, 124.4, 126.2, 130.3, 132.2, 134.7, 
138.5, 151.0, 154.2, 163.0, 163.9, 167.8, 169.7. 
Hydrochloridric salt of {[2-(acetyloxy)benzoyl]oxy}methyl3-[2-amino-3-hydroxybutoxy]-4-(3-
nitrooxypropoxy)benzoate (43). 
The crude product was tritured with dry Et2O to give the title compound as a white solid; yield: 70 
%. m.p.: 87.5-88.5 °C. 1H-NMR (CDCl3)  1.40 (d, 3H, -CHCH3), 2.08 (m, 2H, -OCH2CH2-), 2.24 
(s, 3H, CH3CO-), 3.95 (t, 2H, -OCH2CH2-), 4.26 (m, 1H, -CHCH3), 4.35 (m, 1H, -OH), 4.44 (t, 2H, 
-CH2ONO2), 6.01 (s, 2H, -OCH2O-), 6.90 (d, 1H, C6H3), 7.00 (d, 1H, C6H4), 7.22 (t, 1H, C6H4), 
7.47 (t, 1H, C6H4), 7.73 (s, 1H, C6H3), 7.82 (d, 1H, C6H3), 7.95 (d, 1H, C6H4), 8.83 (svvbr, 3H, 
NH3
+). 13C-NMR (CDCl3)  13.2,19.5, 19.9, 25.5, 64.1, 65.2, 69.1, 79.0, 120.5, 120.9, 122.9, 125.2, 
129.3, 131.1, 133.7, 137.4, 150.0, 153.2, 162.0, 162.2, 162.9, 165.1, 168.7. 
Hydrochloridric salt of {[2-(acetyloxy)benzoyl]oxy}methyl-3-[(3-[aminopropanoyl)oxy]-4-[2,3-
bis(nitrooxy)propoxy]benzoate (44) 
The crude product was tritured with dry Et2O to give the title compound as a foam; yield: 79 %. 
1H-
NMR (DMSO-d6)  2.26 (s, 3H, CH3CO-), 3.02-3.13 (m, 4H, -CH2CH2NH2), 4.46-4.62 (m, AMX-
like system, 2H, -OCH2CH-), 4.85-5.06 (m, AMX-like system, 2H, -CHCH2ONO2), 5.82-5.87 (m, 
1H, -CHCH2ONO2), 6.15 (s, 2H, -OCH2O-), 7.28 (d, 1H, C6H3), 7.36-7.47 (m, 2H, C6H3 + C6H4), 
7.71-7.74 (m, 1H, C6H4), 7.76-7.77 (m, 1H, C6H3), 7.95-8.00 (m, 2H, C6H3 + C6H4), 8.33 (svvbr, 
2H, -NH2). 
13C-NMR (CDCl3)  20.6, 31.0, 34.3, 66.2, 69.7, 77.4, 80.3, 113.8, 121.5, 121.9, 124.2, 
124.5, 126.3, 129.6, 131.5, 135.1, 138.8, 150.1, 153.7, 163.4, 166.4, 168.1, 169.0. 
Solubility study.  
The solubility of the compounds in water was determined at 25 ±1 °C, adding excess amounts of 
the compounds to water in test tubes; the mixtures were sonicated for 10 min and kept under 
magnetic stirring for 30 min. This time was chosen to minimize hydrolysis during the test. After 
filtration, an aliquot of the filtrate was diluted with an appropriate amount of water, and analysed by 
HPLC for the quantitation of the compounds, as reported in the stability study experimental section. 
Stability Studies 
Evaluation of stability in aqueous buffered solutions. A solution of each compound (10 mM) in 
acetonitrile/water (50/50, v/v) was added to HCl 0.1 M or to phosphate buffer pH 7.4 (50 mM) 
preheated to 37 °C; the final concentration of the compound was 100 M. The resulting solution 
was maintained at 37  0.5 °C and, at appropriate time intervals, a 20 L aliquot of reaction 
solution was analyzed by RP-HPLC, as described below. 
Evaluation of stability in human serum. A solution of each compound (10 mM) in 
acetonitrile/water (50/50, v/v) was added to human serum (from human male AB plasma, Sigma) 
preheated to 37 °C; the final concentration of the compound was 200 M. The resulting solution 
was incubated at 37  0.5 °C and, at appropriate time intervals, 300 L of reaction mixture were 
withdrawn and added to 300 L of acetonitrile containing 0.1% trifluoroacetic acid, in order to 
deproteinize the serum. The sample was sonicated, vortexed and then centrifuged for 10 min at 
2150 g; the clear supernatant was filtered through 0.45 m PTFE filters (Alltech) and analyzed by 
RP-HPLC. The reverse-phase HPLC procedure separated and quantitated the remaining compound 
and the products of hydrolysis (ASA, SA, nirooxy-substituted carboxylic acid). 
HPLC analyses were performed with a HP 1100 chromatograph system (Agilent Technologies, Palo 
Alto, CA, USA) equipped with a quaternary pump (model G1311A), a membrane degasser 
(G1379A), and a diode-array detector (DAD) (model G1315B) integrated into the HP1100 system. 
Data were analyzed by the HP ChemStation system (Agilent Technologies). The analytical column 
was a Nucleosil 100-5C18 Nautilus (250 × 4.6 mm, 5 μm particle size) (Macherey-Nagel). The 
samples were analyzed using a gradient method, employing a mobile phase consisting of 
acetonitrile/water with 0.1% trifluoroacetic acid 40/60 (v/v) over the first 2 min, grading to 60/40 at 
11 min, keeping 60/40 until 16 min, and then returning to 40/60 at 20 min. The flow-rate was 1.2 
mL/min. The injection volume was 20 L (Rheodyne, Cotati, CA). The column effluent was 
monitored at 226 nm (for all prodrugs and the majority of metabolites) and at 240 nm (for salicylic 
acid) referenced against a 600 nm wavelength. Quantitation was done using calibration curves of 
compounds and the relative metabolites, chromatographed under the same conditions; the linearity 
of the calibration curves was determined in a concentration range of 1-200µM (r2 > 0.99). 
Inhibition of human platelet aggregation in vitro 
Venous blood samples were obtained from healthy volunteers who had not taken any drug for at 
least two weeks. Volunteers, who were treated according to the Helsinki protocol for biomedical 
experimentation, gave their informed consent to the use of blood samples for research purposes. 
Platelet rich plasma (PRP) was prepared by centrifugation of citrated blood at 200 g for 20 minutes. 
Aliquots (500 L) of PRP were placed in aggregometer (Chrono-log 4902D) cuvettes and 
aggregation was recorded as increased light transmission under continuous stirring (1000 rpm) at 37 
°C for 10 minutes after addition of the stimulus. Collagen at a submaximal concentration (0.8-1.5 
gmL-1) was used as platelet activator in PRP. The compounds under study were preincubated with 
PRP for 10 min before addition of the stimulus (collagen). Drug vehicle alone (0.5% DMSO) added 
to PRP did not affect platelet function in control samples.  
The antiaggregatory activity of the tested compounds is expressed as % inhibition of platelet 
aggregation compared to control samples. For most of the active compounds, IC50 values could be 
calculated by non-linear regression analysis, otherwise % inhibition at maximal concentration tested 
(300 μM) is reported. 
Vasodilator activity 
Thoracic aortas were isolated from male Wistar rats weighing 180-200 g. As few animals as 
possible were used. The purposes of the studies and the protocols used have been approved by the 
Ministry of Health, , Rome, Italy. The endothelium was removed and the vessels were helically cut: 
four to six strips were obtained from each aorta. The tissue was mounted under 1.0 g tension in 
organ baths containing 30 mL of Krebs-bicarbonate buffer, with the following composition (mM): 
NaCl 111.2, KCl 5.0, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.0, NaHCO3 12.0, glucose 11.1, maintained 
at 37 °C and gassed with 95% O2-5% CO2 (pH = 7.4). The aortic strips were allowed to equilibrate 
for 120 min and then contracted with 1 M L-phenylephrine. When the response to the agonist 
reached a plateau, cumulative concentrations of the vasodilating agent were added. Results are 
expressed as EC50 ± SE (M). The effects of 1 M ODQ on relaxation were evaluated in separate 
series of experiments, in which the conpound was added to the organ bath 5 minutes before 
contraction. Responses were recorded by an isometric transducer connected to the MacLab System 
PowerLab. Addition of drug vehicle (DMSO) had no appreciable effect on contraction. 
 
Anti-inflammatory activity. 
Male Wistar rats, weighing 180-200 g (Harlan, S. Pietro al Natisone, Italy) were individually 
housed in hanging stainless-steel cages with grid floors, at constant room temperature (25 ± 1 °C) 
and humidity (60 ± 5%), with an artificial 12:12 h light/dark cycle. Acute edema was induced in 
conscious rats by intraplantar injection into the right hind paw of 0.1 ml of 1% carrageenan, 
suspended in 1% carboxymethylcellulose (CMC). Immediately after carrageenan injection, 
compound or vehicle (1% CMC) was administered intragastrically to different groups of rats in a 
volume of 10 mLkg-1. ASA was administered as reference drug at the dose of 120 mgkg-1 and the 
two selected NO-donor ASA pro-drugs, 38 and 49, were administered at a dose equimolar to 120 
mgkg-1 ASA. Groups of 6 animals were used. Paw volume was measured with a water 
plethysmometer (Basile, Comerio, Italy) immediately before carrageenan injection and 3 hours 
afterwards. The edema reduction in treated animals was expressed as percentage inhibition of the 
edema observed in vehicle-treated animals, taken as 100. The results are presented as means ± 
SEM. Statistical analysis was performed with ANOVA, followed by the Dunnett test. 
Gastrotoxicity. 
Male Wistar rats, weighing 180-200 g (Harlan, S. Pietro al Natisone, Italy) were individually 
housed in hanging stainless-steel cages with grid floors, at constant room temperature (25 ± 1 °C) 
and humidity (60 ± 5%), with an artificial 12:12 h light/dark cycle. They were deprived of food but 
not of water 24 h before the experiments. By the intragastric route, groups of rats (n = 6) were given 
ASA 120 mgkg-1 or equimolar doses of the two selected NO-donor ASA pro-drugs, 38 and 49 (1% 
CMC as vehicle). Rats were killed 3 h after administration of the compound. Immediately after 
death, the stomach was removed, opened along the lesser curvature and examined, to assess 
mucosal lesions. The stomach was laid on a flat surface under a stereomicroscope. The glandular 
mucosa was examined and each individual hemorrhagic lesion was measured along its greatest 
length (<1 mm: rating = 1; 1-2 mm: rating = 2; >2 mm: rating according to their greatest length). 
The lengths of the lesions were summed to give an overall total, designated as the lesion index, for 
each stomach. The results are presented as means ± SEM. Statistical analysis was performed with 
ANOVA, followed by the Newman-Keuls test. 
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z = CH2, (CH2)2, (CH2)3, (CH)CH3,
      (CH(CH(OH)CH3))
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7 n = 1
8 n = 2
5 n = 1, X = Br
















9 z = (CH2)2, n = 1
10 z = (CH2)2, n = 2
11 z = CH2, n = 1
12 z = (CH2)3, n = 1
13 z = (CH)CH3, n = 1
14 z = (CH(CH(OTBDMS)CH3)), n = 1
15 z = (CH2)2, n = 1
16 z = (CH2)2, n = 2
17 z = CH2, n = 1
18 z = (CH2)3, n = 1
19 z = (CH)CH3, n = 1
20 z = (CH(CH(OTBDMS)CH3)), n = 1
 
i) Br(CH2)3Br or Br(CH2)4Cl, KHCO3, CH3CN, 70 °C; ii) AgNO3, CH3CN, 70 °C; iii) EDC-HCl, 
DMAP, N-BOCaminoacid, CH2Cl2; iv) KMnO4, acetone; v) BrCH2CH=CH2, KHCO3,CH3CN, 70 























































i) Cs2CO3, DMF; ii) 1,4-dioxane HCl or TFA, CH2Cl2 
 










(CH2)2 1 15 30  38 
(CH2)2 2 16 31 39 
CH2 1 17 32 40 
(CH2)3 1 18 33 41 
(CH)CH3 1 19 34 42 
(CH(CH(OTBDMS)CH3)) 1 20 35 43 
BOC
 



































































Br(CH2)3Br, CH3CN, K2CO3, 70 °C; ii) AgNO3, CH3CN, 70 °C; iii) 1N NaOH, MeOH, r.t.; iv) 29, 
Cs2CO3, DMF. 
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Table 1. Physicochemical characterization (melting point and water solubility), stability in buffered 
solutions, stability in human serum (half-life, maximal amounts of aspirin released (%) and AUC 






Stability in buffered 
solutions 











 (min)[c] t1/2 (min) 





















































28 - - - - - - 0.87  0.44[g] 
48 - - - - - - 7.4  5.0[g] 
[a] SEM < 1; [b] SEM < 1%; [c] SEM < 0.5; [d] % unchanged after 3 h; [e] SEM = 0.2; [f] SEM < 1.5%; [g] due to the low activity of the compound, IC50 could 
not be calculated: in this case the percent of inhibition at 300 μM ± SE is reported. 
Figure 1. A. Concentration over time of the prodrug 38 and its metabolites in human serum during 
3 hours’ incubation. B. Detail of concentration of compounds during the first 10 min of incubation. 






















































Figure 2. A. Concentration over time of the prodrug 49 and its metabolites in human serum during 
3 hours’ incubation. B. Detail of concentration of compounds over the first 10 min of incubation. 





















































Figure 3. Correlation between ASA released during the first 10 minutes of incubation in human 
serum (area under curve, AUC0-10) and antiaggregatory activity (IC50). 





















Figure 4. A. Anti-inflammatory effects of aspirin and NO-donor ASA prodrugs, 38 and 49, on 
carrageenan-induced paw edema in conscious rats. The aspirin-like compounds were administered 
by the intragastric route at doses equimolar to aspirin, 120 mg/kg, at the same time as carrageenan, 
and their effects were evaluated 3 h later. Results are expressed as the percentage inhibition of 
edema versus the vehicle-treated group, taken arbitrarily as 100. () p < 0.01 versus vehicle 
(ANOVA, followed by the Dunnett test). Values are means ± SEM (n= 6 rats per group). B. Gastric 
ulcerogenic effects of aspirin, and NO-donor ASA prodrugs, 38 and 49, in conscious rats. The 
aspirin-like compounds were administered by the intragastric route at doses equimolar to aspirin, 
120 mg/kg, and the stomach examined 3 h later. Gastric lesions were measured along the greatest 
length, and the cumulative length in millimeters was designated as the “lesion index” for each 
stomach. All the compounds tested produced significantly less gastric damage than aspirin () p 
< 0.01; (ANOVA and the Newman-Keuls test). Values are means ± SEM (n= 6 rats per group). 
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